Bagdonaite, Ieva http://orcid.org/0000-0002-9383-8448
Marinova, Irina N. http://orcid.org/0000-0002-3626-7095
Rudjord-Levann, Asha M. http://orcid.org/0000-0002-9966-0345
Pallesen, Emil M. H.
King-Smith, Sarah L.
Karlsson, Richard http://orcid.org/0000-0003-0448-6135
Rømer, Troels B. http://orcid.org/0000-0002-0832-2667
Chen, Yen-Hsi
Miller, Rebecca L. http://orcid.org/0000-0001-8574-1948
Olofsson, Sigvard
Nordén, Rickard http://orcid.org/0000-0002-3866-7228
Bergström, Tomas
Dabelsteen, Sally http://orcid.org/0000-0002-4279-8060
Wandall, Hans H. http://orcid.org/0000-0003-0240-9232
Funding for this research was provided by:
European Commission (GlycoSkin H2020-ERC)
Lundbeckfonden (R219-2016-545)
Article History
Received: 13 January 2023
Accepted: 18 October 2023
First Online: 2 November 2023
Competing interests
: Unrelated to the presented work, HHW owns stocks and is a consultant for and co-founder of EbuMab, ApS, Hemab, ApS, and GO-Therapeutics, Inc. All other authors declare no competing interests.